Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2005 monograph topics are sildenafil citrate for pulmonary arterial hypertension, paracalcitol capsules, galsulfase, dalbavancin, and febuxostat. The DUE is on paricalcitol capsules.
PettengellK., MynhardtJ., KluytsT.Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.Aliment Pharmacol Ther.2004; 20: 475–481.
4.
KohnoS., MasaokaT., YamaguchiH.A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.Scand J Infect Dis.2004; 36: 372–379.
5.
NakaiT., UnoJ., IkedaF., TawaraS., NishimuraK., MiyajiM.In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.Antimicrob Agents Chemother.2003; 47: 1376–1381.
6.
TakakuraS., FujiharaN., SaitoT.National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.J Antimicrob Chemother.2004; 53: 283–289.
7.
Espinel-IngroffA.In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol.2003; 20: 121–136.
8.
WarnP.A., MorrisseyG., MorrisseyJ., DenningD.W.Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.J Antimicrob Chemother.2003; 51: 913–919.
9.
NinomiyaM., MikamoH., TanakaK., WatanabeK., TamayaT.Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.J Antimicrob Chemother.2005; 55: 587–590.
10.
ClemonsK.V., EspirituM., ParmarR., StevensD.A.Combination therapy (Rx) studies using AmBisome (Ambi), amphotericin B deoxycholate (Amb), caspofungin (CAS), micafungin (MIC) and voriconazole (VCZ) against CNS aspergillosis. Abstract M-1140 presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 – November 2, 2004; Washington, DC.
11.
DennisC.G., GrecoW.R., SlocumH.K.Combination micafungin (Mica) and amphotericin B desoxycholate (Amb-d) has in vitro antagonism but prolongs survival in the p47phox-/-mouse model of chronic granulomatous disease (CGD) with experimental pulmonary aspergillosis. Abstract M-232 presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 – November 2, 2004; Washington DC.
12.
LuqueJ.C., ClemonsK.V., StevensD.A.Efficacy of micafungin alone or in combination against systemic murine aspergillosis.Antimicrob Agents Chemother.2003; 47: 1452–1455.
13.
ErnstE.J., RolingE.E., PetzoldC.R., KeeleD.J., KlepserM.E.In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.Antimicrob Agents Chemother.2002; 46: 3846–3853.
14.
KishinoS., OhnoK., ShimamuraT., FurukawatodoH.Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients.Clin Transplant.2004; 18: 676–680.
15.
ShimoedaS., OhtaS., KobayashiH.Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus.Biol Pharm Bull.2005; 28: 477–480.
16.
de WetN., Llanos-CuentasA., SuleimanH.Micafungin (FK463) dose response and comparison with fluconazole in oesophageal candidiasis. Abstract 83943 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Available at: http://www.asm.org/memonly/abstracts/abstractview.asp?AbstractID=83943. Accessed on March 17, 2005.
17.
de WetN., Llanos-CuentasA., SuleimanJ.A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.Clin Infect Dis.2004; 39: 842–849.
18.
SuleimanJ., NegraM.D., Llanos-CuentasA., TiconaE., RexJ.H., BuellD.N.Open label study of micafungin in the treatment of esophageal candidiasis (EC). Abstract 70107presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA. Available at: http://www.asm.org/memonly/abstracts/abstractview.asp?AbstractID=70107. Accessed on March 17, 2005.
19.
van BurikJ.A., RatanatharathornV., StepanD.E.Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.Clin Infect Dis.2004; 39: 1407–1416.
20.
YokoteT., AkiokaT., OkaS.Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy.Ann Hematol.2004; 83: 64–66.
21.
OtaS., TanakaJ., KahataK.Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study.Int J Hematol.2004; 79: 390–393.
22.
MiyazakiY., MoriM., TashiroT., KohnoS.Clinical efficacy for the combination of micafungin with amphotericin B against pulmonary aspergillosis. Abstract M-1052 presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 – November 2, 2004; Washington, DC.
23.
LinP., MickieneD., PetraitisV.Micafungin and amphotericin B have no pharmacokinetic interaction when used in combination therapy. Abstract M-227 presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 – November 2, 2004; Washington, DC.
